BlackRock Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

BlackRock Group’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$136K	Buy	2,383 +177	+8%	+$10.7K	﹤0.01%	2765
2016 Q3	$136K	Buy	2,206 +1,146	+108%	+$81K	﹤0.01%	2755
2016 Q2	$60K	Sell	1,060 -26	-2%	-$1.58K	﹤0.01%	2886
2016 Q1	$70K	Buy	1,086 +561	+107%	+$45.4K	﹤0.01%	2849
2015 Q4	$74K	Sell	525 -2,572	-83%	-$349K	﹤0.01%	2761
2015 Q3	$300K	Buy	3,097 +1,300	+72%	+$155K	﹤0.01%	2397
2015 Q2	$273K	Buy	+1,797	New	+$297K	﹤0.01%	2483

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Group's KDNY Position: Q4 2016 in Review

BlackRock Group increased its Chinook Therapeutics, Inc. Common Stock (KDNY) stake by 8% in Q4 2016, buying an estimated $10.7K and bringing the position to 2,383 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #2765.

BlackRock Group first reported a position in KDNY in Q2 2015 and has held it in 7 quarters since. The position peaked at $300K in Q3 2015. 87 funds tracked by Wall St. Rank hold KDNY as of Q4 2016.

BlackRock Group held 2,383 shares of Chinook Therapeutics, Inc. Common Stock worth $136K as of Q4 2016.
BlackRock Group bought 177 Chinook Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $10.7K.
Chinook Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2765 holding.
BlackRock Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and has held it in 7 quarters since.
BlackRock Group's Chinook Therapeutics, Inc. Common Stock position peaked at $300K in Q3 2015.
87 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.